COVID-19 Therapeutics

New and Notable: COVID-19 Therapeutics Announcements

January 24, 2022: UPDATE -- Allocation of Bamlanivimab/Etesevimab and REGEN-COV Therapeutics Paused
December 31, 2021: UPDATE -- Allocation of Bamlanivimab/Etesevimab and REGEN-COV Therapeutics
December 29, 2021: Allocation of Bamlanivimab/Etesevimab and REGEN-COV Therapeutics
December 23, 2021: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults
December 23, 2021: ASPR Pauses Allocation of Bamlanivimab and Etesevimab Together, Etesevimab Alone, and REGEN-COV
December 22, 2021: FDA Authorizes First Oral Antiviral for Treatment of COVID-19

COVID-19 therapeutics can be used to prevent or treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. Prevention and early treatment for eligible patients can help improve patient outcomes, reduce stress on healthcare facilities, and even save lives.

HHS/ASPR has purchased supplies of COVID-19 therapeutic products and we are working with state and territorial health departments as well as national healthcare and medical organizations and associations to get the treatments into the hands of healthcare providers quickly, with a focus on areas of the country hardest hit by the pandemic.